Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Portfolio News / Karina Tin January 8, 2024 Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Read More »
Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease Portfolio News / Karina Tin January 3, 2024 Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease Read More »
Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing Portfolio News / Karina Tin January 3, 2024 Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing Read More »
